Ascendis Pharma A/S Insider Trading Activity
Every SEC Form 4 insider transaction reported for Ascendis Pharma A/S (ASND), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are ASND insiders buying or selling?
In the last 12 months, Ascendis Pharma A/S insiders reported 5 open-market purchases ($777.1K) and 3 sales ($5.5M) — net selling of $4.7M. Since May 2026, Trabud has recorded 8 Form 4 filings for ASND: 5 buys ($777.1K) and 3 sells ($5.5M).
Source: SEC EDGAR Form 4
What stands out
- The largest open-market purchase in the last 12 months was $492.7K by Jean Jacques Bienaime (Director) on Aug 19, 2026. SEC ↗
- The most recent open-market purchase was reported on Aug 19, 2026 (2 months ago).
Key Statistics (May 2026 – Sep 9, 2026)
Total Form 4 filings
8
SEC EDGAR
Insider filers
5
Insider buys (5)
$777.1K
Insider sells (3)
$5.5M
Insider sentiment
Net sellingNet insider flow of $4.7M in net selling since May 2026, and $4.7M in net selling over the last 12 months. 1 insider buy in the last 90 days.
Recent ASND insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 9, 2026 | Mads Bodenhoff | SVP & PAO | Sale | 3.0K | $270.19 | $810.6K | SEC ↗ |
| Sep 3, 2026 | Lars Holtug | Director | Sale | 236 | $264.13 | $62.3K | SEC ↗ |
| Aug 19, 2026 | Jean Jacques Bienaime | Director | Purchase | 2.0K | $246.33 | $492.7K | SEC ↗ |
| Jun 2, 2026 | Scott Thomas Smith | EVP & Chief Financial Officer | Purchase | 100 | $219.00 | $21.9K | SEC ↗ |
| Jun 1, 2026 | Jean Jacques Bienaime | Director | Purchase | 500 | $223.12 | $111.6K | SEC ↗ |
| Jun 1, 2026 | Scott Thomas Smith | EVP & Chief Financial Officer | Purchase | 250 | $223.32 | $55.8K | SEC ↗ |
| May 27, 2026 | Jean Jacques Bienaime | Director | Purchase | 400 | $237.80 | $95.1K | SEC ↗ |
| May 12, 2026 | Flemming Steen Jensen | EVP & Product Supply and Quality | Sale | 19.5K | $238.49 | $4.6M | SEC ↗ |
Showing the 8 most recent of 8 Form 4 filings for Ascendis Pharma A/S.
Most active ASND insiders
- Jean Jacques Bienaime3 filings
- Scott Thomas Smith2 filings
- Flemming Steen Jensen1 filing
- Lars Holtug1 filing
- Mads Bodenhoff1 filing
Ask anything about ASND insider activity
Use Trabud's AI agent to query Ascendis Pharma A/S's Form 4 history in plain English — "Show me ASND CEO purchases this year" or compare it against any other ticker.
Open the AI agentASND insider trading FAQ
Are Ascendis Pharma A/S insiders buying or selling?
In the last 12 months, Ascendis Pharma A/S insiders reported 5 open-market purchases ($777.1K) and 3 sales ($5.5M) — net selling of $4.7M. Since May 2026, Trabud has recorded 8 Form 4 filings for ASND: 5 buys ($777.1K) and 3 sells ($5.5M). Over the full record that is net selling of $4.7M.
How many insiders trade ASND stock?
5 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Ascendis Pharma A/S. The most recent filing was accepted on Sep 9, 2026.
Where does Trabud get ASND insider trading data?
All ASND insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.